Rovi ready to supply Moderna's vaccine to markets outside the United States from early 2021

Rovi is prepared to supply the Moderna vaccine to markets outside the United States from the beginning of 2021, according to a presentation sent to the National Securities Market Commission (CNMV) regarding the updating of its strategy on the occasion of its 2020 Capital Market Day.

Specifically, following the agreement with Moderna, Rovi will provide vial filling and packaging capacity through the acquisition of a new production line and equipment for composition, filling, automatic visual inspection and labelling to support the production of hundreds of millions of doses of the candidate vaccine.

Thus, Rovi will have three plants involved in the agreement with Moderna and the existing annual capacity of vials will be 600 million doses.

Moderna has confirmed advanced discussions with the European Commission to supply Europe with 80 million doses of mRNA vaccine against COVID-19 (mRNA-1273), plus a purchase option for up to 80 million more doses.

Moderna announced last week that the Data Safety Monitoring Board (DSMB), independently appointed by the US National Institutes of Health (NIH), reported that the Phase 3 study of mRNA-1273, its mVID-19 vaccine candidate, has shown 94.5% efficacy in early analyses.

In addition, Rovi confirmed its growth targets for 2023, when it expects to roughly double its 2018 operating revenues to 303.2 million euros and multiply its recurring gross operating profit (Ebitda) of 63 million euros by 2.5.

Rovi said that the next growth phase will be driven by several key catalysts (Enoxaparin biosimilar, Risperidona-ISM, LetrozolISM, M&A activities or contract with Moderna), backed by a "solid and growing" pharmaceutical specialties business.